Compare Dolby Laboratories, Inc. (DLB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Dolby Laboratories, Inc. trades at $58.75 (market cap $5.47B), while IDEXX Laboratories, Inc. trades at $518.89 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.4× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DLB | IDXX | |
|---|---|---|
Market Cap | $5.47B | $40.43B |
Volume | 1,058,284 | 692,164 |
Sector | Technology | Health |
52-Week High | $70.09 | $766.68 |
52-Week Low | $48.51 | $504.70 |
Typical Hold Time | 98 Days | 46 Days |
Enterprise Value | $4.85B | $41.32B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.67, up 0.55% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 87.61% gross margins and 16.7% net income margins, though revenue has remained flat around $1.3B. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten.
DLB offers value with analyst consensus target of $90.33 (54% upside) but faces near-term execution risks and licensing volatility. The stock trades at reasonable valuations (P/E 24.87, P/S 4.15) with solid cash flow generation, though technical indicators suggest caution amid bearish momentum signals.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
